{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:24:15Z","timestamp":1789039455145,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jid.2025.07.032","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T23:15:49Z","timestamp":1756163749000},"page":"826-829.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Phase 2, Randomized, Placebo-Controlled Study of Bermekimab in Moderate-to-Severe Hidradenitis Suppurativa"],"prefix":"10.1016","volume":"146","author":[{"given":"Seth","family":"Forman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Kephart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6249-0664","authenticated-orcid":false,"given":"Takayuki","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6641-1038","authenticated-orcid":false,"given":"Jeff","family":"Pawlikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9405-0479","authenticated-orcid":false,"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.07.032_bib1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0161-5890(96)00017-X","article-title":"Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor","volume":"33","author":"Garrone","year":"1996","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jid.2025.07.032_bib2","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jid.2019.10.024","article-title":"A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain","volume":"140","author":"Gottlieb","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.07.032_bib3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjd.19435","article-title":"The epidemiology of hidradenitis suppurativa","volume":"183","author":"Ingram","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.07.032_bib4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.07.032_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130522","article-title":"Compartmentalized cytokine responses in hidradenitis suppurativa","volume":"10","author":"Kanni","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2025.07.032_bib6","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.07.032_bib7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2025.07.032_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2025.07.032_bib9","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction","volume":"139","author":"Witte-H\u00e4ndel","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.07.032_bib10","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaad.2021.11.015","article-title":"Development of a patient-reported outcome questionnaire to assess signs and symptoms of hidradenitis suppurativa: the Hidradenitis Suppurativa Symptom Diary","volume":"88","author":"Alavi","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.07.032_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.07.032_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaad.2019.05.065","article-title":"Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: a systematic review","volume":"82","author":"Amir Ali","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.07.032_bib13","series-title":"(adalimumab) [package insert]","year":"2024"},{"key":"10.1016\/j.jid.2025.07.032_bib14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2025.07.032_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2025.07.032_bib16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25023565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25023565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:28:45Z","timestamp":1779942525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X25023565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0022202X25023565"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.07.032","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2, Randomized, Placebo-Controlled Study of Bermekimab in Moderate-to-Severe Hidradenitis Suppurativa","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.07.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}